146 related articles for article (PubMed ID: 37021492)
1. Integrated virtual screening and molecular dynamics simulation approaches revealed potential natural inhibitors for DNMT1 as therapeutic solution for triple negative breast cancer.
Bashir Y; Noor F; Ahmad S; Tariq MH; Qasim M; Tahir Ul Qamar M; Almatroudi A; Allemailem KS; Alrumaihi F; Alshehri FF
J Biomol Struct Dyn; 2024; 42(3):1099-1109. PubMed ID: 37021492
[TBL] [Abstract][Full Text] [Related]
2. Alpha-mangostin as an inhibitor of GSK3β in triple-negative breast cancer.
Dewi C; Fristiohady A; Amalia R; Bunggulawa EJ; Muchtaridi M
J Biomol Struct Dyn; 2023 Jul; 41(10):4515-4521. PubMed ID: 35465844
[TBL] [Abstract][Full Text] [Related]
3. DNMT1: A key drug target in triple-negative breast cancer.
Wong KK
Semin Cancer Biol; 2021 Jul; 72():198-213. PubMed ID: 32461152
[TBL] [Abstract][Full Text] [Related]
4. Identification of Genes Hub Associated with Triple-Negative Breast Cancer and Cannabidiol Analogs Potential Inhibitory Agents: An In-silico Study.
Contreras-Puentes N; Alviz-Amador A; Zabaleta-Guzman JA; Pineda Aleman R; Tarón Dunoyer A
Asian Pac J Cancer Prev; 2024 May; 25(5):1649-1661. PubMed ID: 38809637
[TBL] [Abstract][Full Text] [Related]
5. Integrated molecular modeling and dynamics approaches revealed potential natural inhibitors of NF-κB transcription factor as breast cancer therapeutics.
Zubair M; Khalil S; Rasul I; Nadeem H; Noor F; Ahmad S; Alrumaihi F; Allemailem KS; Almatroudi A; Alshehri FF; Alshehri ZS
J Biomol Struct Dyn; 2023; 41(24):14715-14729. PubMed ID: 37301608
[TBL] [Abstract][Full Text] [Related]
6. Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative Breast Cancer Therapeutics Targeting the BRCT Domain of BARD1 Receptor.
Chatterjee P; Karn R; Emerson IA; Banerjee S
Mol Biotechnol; 2024 Apr; 66(4):718-736. PubMed ID: 36732462
[TBL] [Abstract][Full Text] [Related]
7. A drug design strategy based on molecular docking and molecular dynamics simulations applied to development of inhibitor against triple-negative breast cancer by Scutellarein derivatives.
Akash S; Aovi FI; Azad MAK; Kumer A; Chakma U; Islam MR; Mukerjee N; Rahman MM; Bayıl I; Rashid S; Sharma R
PLoS One; 2023; 18(10):e0283271. PubMed ID: 37824496
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoinformatics approach for the screening of Kovidra
More-Adate P; Lokhande KB; Shrivastava A; Doiphode S; Nagar S; Singh A; Baheti A
J Biomol Struct Dyn; 2024 May; 42(8):4263-4282. PubMed ID: 37288734
[TBL] [Abstract][Full Text] [Related]
9.
Yang R; Lu M; Ming L; Chen Y; Cheng K; Zhou J; Jiang S; Lin Z; Chen D
Int J Nanomedicine; 2020; 15():9061-9074. PubMed ID: 33239874
[TBL] [Abstract][Full Text] [Related]
10. Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer: An in silico and in vitro study.
Sinha S; Patel S; Athar M; Vora J; Chhabria MT; Jha PC; Shrivastava N
Int J Biol Macromol; 2019 Nov; 140():454-468. PubMed ID: 31404596
[TBL] [Abstract][Full Text] [Related]
11. Identification of Novel Natural Dual HDAC and Hsp90 Inhibitors for Metastatic TNBC Using e-Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Studies.
AbdElmoniem N; H Abdallah M; M Mukhtar R; Moutasim F; Rafie Ahmed A; Edris A; Ibraheem W; Makki AA; M Elshamly E; Elhag R; Osman W; A Mothana R; Alzain AA
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838758
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic-based cancer therapeutics: new potential HDAC8 inhibitors.
Hassanzadeh M; Mahernia S; Caprini G; Fossati G; Adib M; Moakedi F; Amanlou M
J Biomol Struct Dyn; 2022 Jan; 40(1):297-311. PubMed ID: 32886033
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent DNMT1 inhibitors against sickle cell disease using structural-based virtual screening, MM-GBSA and molecular dynamics simulation-based approaches.
Ala C; Joshi RP; Gupta P; Ramalingam S; Sankaranarayanan M
J Biomol Struct Dyn; 2024; 42(1):261-273. PubMed ID: 37061929
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA methylation for treating triple-negative breast cancer.
Yu J; Zayas J; Qin B; Wang L
Pharmacogenomics; 2019 Nov; 20(16):1151-1157. PubMed ID: 31755366
[TBL] [Abstract][Full Text] [Related]
15. Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach.
Lamichhane S; Rai RP; Khatri A; Adhikari R; Shrestha BG; Shrestha SK
J Biomol Struct Dyn; 2023 Feb; 41(3):897-911. PubMed ID: 34957911
[TBL] [Abstract][Full Text] [Related]
16. MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.
Chen F; Luo N; Hu Y; Li X; Zhang K
Cell Physiol Biochem; 2018; 47(5):2147-2158. PubMed ID: 29975921
[TBL] [Abstract][Full Text] [Related]
17. Potential target identification for breast cancer and screening of small molecule inhibitors: A bioinformatics approach.
Agarwal S; Kashaw SK
J Biomol Struct Dyn; 2021 Apr; 39(6):1975-1989. PubMed ID: 32186248
[TBL] [Abstract][Full Text] [Related]
18. In silico molecular docking and physicochemical property studies on effective phytochemicals targeting GPR116 for breast cancer treatment.
Muthiah I; Rajendran K; Dhanaraj P
Mol Cell Biochem; 2021 Feb; 476(2):883-896. PubMed ID: 33106912
[TBL] [Abstract][Full Text] [Related]
19. Quantum evaluation and therapeutic activity of (E)-N-(4-methoxyphenyl)-2-(4-(3-oxo-3-phenylprop-1-en-1-yl) phenoxy)acetamide and its modified derivatives against EGFR and VEGFR-2 in the treatment of triple-negative cancer via in silico approach.
Ipinloju N; Ibrahim A; da Costa RA; Adigun TB; Olubode SO; Abayomi KJ; Aiyelabegan AO; Esan TO; Muhammad SA; Oyeneyin OE
J Mol Model; 2023 Apr; 29(5):159. PubMed ID: 37099048
[TBL] [Abstract][Full Text] [Related]
20. Identification of a potential DNA methyltransferase (DNMT) inhibitor.
Jan Z; Ahmed WS; Biswas KH; Jithesh PV
J Biomol Struct Dyn; 2024 Jun; 42(9):4730-4744. PubMed ID: 37424222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
